Evidence-based approach for interpretation of Epstein-Barr virus serological patterns.

Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Journal of clinical microbiology (Impact Factor: 4.23). 08/2009; 47(10):3204-10. DOI: 10.1128/JCM.00164-09
Source: PubMed

ABSTRACT Diagnosis of Epstein-Barr virus (EBV) infection is based on clinical symptoms and serological markers, including the following: immunoglobulin G (IgG) and IgM antibodies to the viral capsid antigen (VCA), heterophile antibodies, and IgG antibodies to the EBV early antigen-diffuse (EA-D) and nuclear antigen (EBNA-1). The use of all five markers results in 32 possible serological patterns. As a result, interpretation of EBV serologies remains a challenge. The purpose of this study was to use a large population of patients to develop evidence-based tools for interpreting EBV results. This study utilized 1,846 serum specimens sent to the laboratory for physician-ordered EBV testing. Chart review was performed for more than 800 patients, and diagnoses were assigned based on physician-ordered testing, clinical presentation, and patient history. Testing for all five EBV antibodies was performed separately on all serum samples using the Bio-Rad BioPlex 2200 system. Presumed EBV diagnosis (based on previous publications) was compared to EBV diagnosis based on a medical record review for each serological pattern. Interestingly, of the 32 possible serological patterns, only 12 occurred in > or = 10 patients. The remaining 20 patterns were uninterpretable because they occurred with such infrequency. Two easy-to-use tables were created to interpret EBV serological patterns based on whether three (EBV VCA IgG, IgM, and heterophile) or five markers are utilized. The use of these two tables allows for interpretation of >95% of BioPlex serological results. This is the first evidence-based study of its kind for EBV serology.


Available from: Bradley A Ford, Dec 31, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: We report the infection of New Zealand white rabbits with Epstein-Barr virus (EBV). Methods: EBV prepared in B95-8 (producer) cells was inoculated to rabbits by combined intranasal and oral routes. Blood and white blood cell (WBC) samples were taken before infection, then on days 8, 28 and 98 post-infection (p.i.). Results: Administration of either 3 × 10(8) (group A, 11 rabbits) or 1 × 10(9) (group B, 10 rabbits) EBV DNA copies per animal induced subacute and/or persistent infection. The IgG antibodies in plasma were detected by ELISA as well as by immunoblot (IB). The IB bands showed mainly antibodies to the BZRF1/Zta transactivation polypeptide (69.2%), the p54 early protein (53.4%) and to the p23 capsid protein (35.8%). No anti-EBNA1 antibody was detected throughout. Viral DNA could be detected by PCR in WBCs and/or spleen of 7 out of 21 infected rabbits (30%), while 60-80% of them showed serologic response. The transiently present EBV DNA was accompanied by LMP1 antigen. Conclusions: Rabbits developed persistent EBV infection in the absence of EBNA1 antibodies and by the lack of typical infectious mononucleosis-like syndrome. The absence of EBNA1 antibody may reflect the lack of EBNA1 in B cells of EBV-inoculated rabbits. © 2014 S. Karger AG, Basel.
    Intervirology 06/2014; 57(5):254-269. DOI:10.1159/000360223 · 1.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been shown that Epstein-Barr virus (EBV) is able to alter the immune response towards self-antigens and may enhance risk of autoimmune diseases such as systemic lupus erythematosus (SLE) in genetically predisposed individuals. In this study, we evaluated the specific antibody immune response against EBV in patients with anti-nuclear autoantibodies (ANA) in comparison with ANA-negative healthy controls. For this purpose, 92 patients with an high anti-ANA reactivity with or without concomitant extractable nuclear antigen (ENA) or double stranded DNA (dsDNA) positivity were selected and compared with 146 healthy donors. We found that anti-EBV-VCA and EA IgG concentrations were significantly higher in ANA-positive patients in comparison to the controls (VCA P<0.0001 and EA P<0,03) as well as in those ANA-positive patients that showed a concomitant ENA positivity (P=0.0002). Interestingly, elevated anti-EBNA-1 IgG was found in a group of patients who had anti SSA/Ro antibodies. Anti-VCA IgM Abs were more frequently found in those patients with a very high titer of ANA (P=0.06); moreover detection of anti-VCA IgM/IgG in absence of anti-EBNA-1 IgG was more frequent in the patient than in the control group. Both these conditions correlate with a recent EBV infection or reactivation. The data suggest that EBV, particularly during acute infection or in its reactivation phase, could be involved in the ANA and ENA autoantibody formation.
    Virus Research 10/2014; 195. DOI:10.1016/j.virusres.2014.09.014 · 2.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Personalized medicine is revolutionizing modern health care. The aim of personalized diagnostics is to provide rapid, portable and simple tests that will reduce diagnosis time. They enable rapid analysis performed near the patient and provide specific details of the patient’s condition so that a personalized treatment can be made. This review focuses on the recent advances in optical diagnostic techniques based on surface plasmon resonance (SPR) and surface-enhanced Raman scattering spectroscopy (SERS) for translational medical diagnostics. In the first part, recent developments in SPR biosensors for infectious disease diagnosis are presented including the first two-dimensional multiplex influenza SPR biosensor for H1N1 (influenza A) and H3N2 (seasonal influenza) detection. In the second part, advances in SERS, which is another ultra-sensitive optical diagnostic technique for various cancer detection applications in pre-clinical and clinical settings, are reviewed.